Polysaccharide dextran-based conjugate for selective co-delivery of two synergistic drugs docetaxel and docosahexaenoic acid to tumor cells

References

• Alibolandi M, Abnous K, Hadizadeh F, et al. (2016). Dextran-poly lactide-co-glycolide polymersomes decorated with folate-antennae for targeted delivery of docetaxel to breast adenocarcinima in vitro and in vivo. J Control Release 241:45–56.
   PubMed Web of Science ®Google Scholar
• Atrafi F, Dumez H, Mathijssen RHJ, et al. (2020). A phase I dose-escalation and pharmacokinetic study of a micellar nanoparticle with entrapped docetaxel (CPC634) in patients with advanced solid tumours. J Control Release 325:191–7.
   PubMed Web of Science ®Google Scholar
• Bedikian AY, DeConti RC, Conry R, et al. (2011). Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann Oncol 22:787–93.
   PubMed Web of Science ®Google Scholar
• Chang N, Zhao Y, Ge N, et al. (2020). A pH/ROS cascade-responsive and self-accelerating drug release nanosystem for the targeted treatment of multi-drug-resistant colon cancer. Drug Deliv 27:1073–86.
   PubMed Web of Science ®Google Scholar
• Chauvin L, Goupille C, Blanc C, et al. (2016). Long chain n-3 polyunsaturated fatty acids increase the efficacy of docetaxel in mammary cancer cells by downregulating Akt and PKCε/δ-induced ERK pathways. Biochim Biophys Acta 1861:380–90.
   PubMed Web of Science ®Google Scholar
• Chen J, Zaal EA, Berkers CR, et al. (2021). Omega-3 fatty acids DHA and EPA reduce bortezomib resistance in multiple myeloma cells by promoting glutathione degradation. Cells 10:2287.
   PubMed Web of Science ®Google Scholar
• Corsetto PA, Colombo I, Kopecka J, et al. (2017). ω-3 Long chain polyunsaturated fatty acids as sensitizing agents and multidrug resistance revertants in cancer therapy. Int J Mol Sci 18:2770.
   PubMed Web of Science ®Google Scholar
• Dong P, Liu J, Lv H, et al. (2022). The enhanced antitumor activity of the polymeric conjugate covalently coupled with docetaxel and docosahexaenoic acid. Biomater Sci 10:3454–65.
   PubMed Web of Science ®Google Scholar
• Du W, Hong L, Yao T, et al. (2007). Synthesis and evaluation of water-soluble docetaxel prodrugs-docetaxel esters of malic acid. Bioorg Med Chem 15:6323–30.
   PubMed Web of Science ®Google Scholar
• Ekladious I, Colson YL, Grinstaff MW. (2019). Polymer-drug conjugate therapeutics: advances, insights and prospects. Nat Rev Drug Discov 18:273–94.
   PubMed Web of Science ®Google Scholar
• Engels FK, Mathot RA, Verweij J. (2007). Alternative drug formulations of docetaxel: a review. Anticancer Drugs 18:95–103.
   PubMed Web of Science ®Google Scholar
• Fodil M, Blanckaert V, Ulmann L, et al. (2022). Contribution of n – 3 long-chain polyunsaturated fatty acids to the prevention of breast cancer risk factors. Int J Environ Res Public Health 19:7936.
   PubMed Web of Science ®Google Scholar
• Giordano C, Plastina P, Barone I, et al. (2020). n – 3 Polyunsaturated fatty acid amides: new avenues in the prevention and treatment of breast cancer. Int J Mol Sci 21:2279.
   PubMed Web of Science ®Google Scholar
• Goupille C, Vibet S, Frank PG, et al. (2020). EPA and DHA fatty acids induce a remodeling of tumor vasculature and potentiate docetaxel activity. Int J Mol Sci 21:4965.
   PubMed Web of Science ®Google Scholar
• Han HS, Lee M, An JY, et al. (2016). A pH-responsive carboxymethyl dextran-based conjugate as a carrier of docetaxel for cancer therapy. J Biomed Mater Res B Appl Biomater 104:789–96.
   PubMed Web of Science ®Google Scholar
• He H, Liu L, Morin EE, et al. (2019). Survey of clinical translation of cancer nanomedicines-lessons learned from successes and failures. Acc Chem Res 52:2445–61.
   PubMed Web of Science ®Google Scholar
• Homsi J, Bedikian AY, Papadopoulos NE, et al. (2010). Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma. Melanoma Res 20:507–10.
   PubMed Web of Science ®Google Scholar
• Hong SJ, Ahn MH, Sangshetti J, et al. (2018). Sugar-based gene delivery systems: current knowledge and new perspectives. Carbohydr Polym 181:1180–93.
   PubMed Web of Science ®Google Scholar
• Hu Q, Lu Y, Luo Y. (2021). Recent advances in dextran-based drug delivery systems: from fabrication strategies to applications. Carbohydr Polym 264:117999.
   PubMed Web of Science ®Google Scholar
• Huang G, Huang H. (2018). Application of dextran as nanoscale drug carriers. Nanomedicine (Lond) 13:3149–58.
   PubMed Web of Science ®Google Scholar
• Huang L, Zhou Y, Gou ZX, et al. (2022). Docosahexaenoic acid reduces hypoglycemia-induced neuronal necroptosis via the peroxisome proliferator-activated receptor γ/nuclear factor-κB pathway. Brain Res 1774:147708.
   PubMed Web of Science ®Google Scholar
• Jiang S, Liu Z, Wu L, et al. (2018). Tumor targeting with docosahexaenoic acid-conjugated docetaxel for inhibiting lung cancer metastasis to bone. Oncol Lett 16:2911–20.
   PubMed Web of Science ®Google Scholar
• Jurczyk M, Kasperczyk J, Wrześniok D, et al. (2022). Nanoparticles loaded with docetaxel and resveratrol as an advanced tool for cancer therapy. Biomedicines 10:1187.
   PubMed Web of Science ®Google Scholar
• Li B, Tan T, Chu W, et al. (2022). Co-delivery of paclitaxel (PTX) and docosahexaenoic acid (DHA) by targeting lipid nanoemulsions for cancer therapy. Drug Deliv 29:75–88.
   PubMed Web of Science ®Google Scholar
• Liu K, Jiang X, Hunziker P. (2016). Carbohydrate-based amphiphilic nano delivery systems for cancer therapy. Nanoscale 8:16091–156.
   PubMed Web of Science ®Google Scholar
• Liu P, Situ JQ, Li WS, et al. (2015). High tolerated paclitaxel nano-formulation delivered by poly (lactic-co-glycolic acid)-g-dextran micelles to efficient cancer therapy. Nanomedicine 11:855–66.
   PubMed Web of Science ®Google Scholar
• Liu Y, Tian Y, Guo Y, et al. (2021). DHA-enriched phosphatidylcholine suppressed angiogenesis by activating PPARγ and modulating the VEGFR2/Ras/ERK pathway in human umbilical vein endothelial cells. Food Sci Biotechnol 30:1543–53.
   PubMed Web of Science ®Google Scholar
• Montero A, Fossella F, Hortobagyi G, et al. (2005). Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 6:229–39.
   PubMed Web of Science ®Google Scholar
• Newell M, Goruk S, Schueler J, et al. (2022). Docosahexaenoic acid enrichment of tumor phospholipid membranes increases tumor necroptosis in mice bearing triple negative breast cancer patient-derived xenografts. J Nutr Biochem 107:109018.
   PubMed Web of Science ®Google Scholar
• Newell M, Mazurak V, Postovit LM, et al. (2021). n – 3 Long-Chain polyunsaturated fatty acids, eicosapentaenoic and docosahexaenoic acid, and the role of supplementation during cancer treatment: a scoping review of current clinical evidence. Cancers (Basel) 13:1206.
   PubMed Web of Science ®Google Scholar
• Picard M, Castells MC. (2015). Re-visiting hypersensitivity reactions to taxanes: a comprehensive review. Clin Rev Allergy Immunol 49:177–91.
   PubMed Web of Science ®Google Scholar
• Piha-Paul SA, Thein KZ, De Souza P, et al. (2021). First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies. Invest New Drugs 39:1047–56.
   PubMed Web of Science ®Google Scholar
• Raza K, Kumar N, Misra C, et al. (2016). Dextran-PLGA-loaded docetaxel micelles with enhanced cytotoxicity and better pharmacokinetic profile. Int J Biol Macromol 88:206–12.
   PubMed Web of Science ®Google Scholar
• Razak SAA, Mohd Gazzali A, Fisol FA, et al. (2021). Advances in nanocarriers for effective delivery of docetaxel in the treatment of lung cancer: an overview. Cancers (Basel) 13:400.
   PubMed Web of Science ®Google Scholar
• Siddiqui RA, Harvey KA, Xu Z, et al. (2011). Docosahexaenoic acid: a natural powerful adjuvant that improves efficacy for anticancer treatment with no adverse effects. Biofactors 37:399–412.
   PubMed Web of Science ®Google Scholar
• Song EA, Kim H. (2016). Docosahexaenoic acid induces oxidative DNA damage and apoptosis, and enhances the chemosensitivity of cancer cells. Int J Mol Sci 17:1257.
   PubMed Web of Science ®Google Scholar
• Sugahara S, Kajiki M, Kuriyama H, et al. (2007). Complete regression of xenografted human carcinomas by a paclitaxel-carboxymethyl dextran conjugate (AZ10992). J Control Release 117:40–50.
   PubMed Web of Science ®Google Scholar
• van Eerden RAG, Mathijssen RHJ, Koolen SLW. (2020). Recent clinical developments of nanomediated drug delivery systems of taxanes for the treatment of cancer. Int J Nanomed 15:8151–66.
   PubMed Web of Science ®Google Scholar
• Wang R, Yang H, Khan AR, et al. (2021). Redox-responsive hyaluronic acid-based nanoparticles for targeted photodynamic therapy/chemotherapy against breast cancer. J Colloid Interface Sci 598:213–28.
   PubMed Web of Science ®Google Scholar
• Weiser MJ, Butt CM, Mohajeri MH. (2016). Docosahexaenoic acid and cognition throughout the lifespan. Nutrients 8:99.
   PubMed Web of Science ®Google Scholar
• Zhang E, Xing R, Liu S, et al. (2019). Current advances in development of new docetaxel formulations. Expert Opin Drug Deliv 16:301–12.
   PubMed Web of Science ®Google Scholar
• Zhou T, Zhu B, Chen F, et al. (2017). Micro-/nanofibers prepared via co-assembly of paclitaxel and dextran. Carbohydr Polym 157:613–9.
   PubMed Web of Science ®Google Scholar